2005
Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors
Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. Journal Of Clinical Oncology 2005, 23: 1875-1884. PMID: 15699481, DOI: 10.1200/jco.2005.03.116.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMononuclear cellsPlasma concentrationsProtein kinase C inhibitorMean maximal plasma concentrationUCN-01Kinase C inhibitorPhase I clinical trialPhase II doseAdvanced solid tumorsPhase II trialMaximal plasma concentrationSignificant interpatient variabilityReverse transcriptase-polymerase chain reactionAlpha-1-acid glycoproteinC inhibitorFibonacci designFU dosePrior fluoropyrimidinesStable diseaseCyclin-dependent kinase inhibitorII trialObjective responseWeekly infusionsI trial
2004
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
Foss FM. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Practice & Research Clinical Haematology 2004, 17: 573-584. PMID: 15494295, DOI: 10.1016/j.beha.2004.08.009.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeAnti-vascular endothelial growth factorChemotherapeutic agentsAllogeneic bone marrow transplantationReceptor tyrosine kinase inhibitorsGrowth factorTransplant conditioning regimensBone marrow transplantationTyrosine kinase inhibitorsClonal hematopoietic disordersEndothelial growth factorNovel chemotherapeutic agentsMatrix metalloproteinase inhibitorsFarnesyl transferase inhibitorsIntensive chemotherapyConditioning regimensSupportive careFavorable cytogeneticsPrognostic factorsAntimetabolite therapyMarrow transplantationMDS patientsTreatment paradigmClinical trialsProtein kinase C inhibitor
2002
Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer
Herbst RS. Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer. Clinical Lung Cancer 2002, 3: s30-s38. PMID: 14720353, DOI: 10.3816/clc.2002.s.006.Peer-Reviewed Original ResearchCell lung cancerVascular endothelial growth factorProtein kinase C inhibitorLung cancerKinase C inhibitorSpecific cellular mechanismsCell cycle inhibitionEGFR tyrosine kinaseSignal transductionTyrosine kinaseKey enzymeReceptor-targeted therapyTreatment of NSCLCTumor growth delayC inhibitorEndothelial growth factorCellular mechanismsOSI-774IMC-C225Advanced NSCLCPoor prognosisMajor classesTargeted therapyNovel agentsTherapeutic improvement
1998
Modulation of a calcium-sensitive nonspecific cation channel by closely associated protein kinase and phosphatase activities
Wilson G, Magoski N, Kaczmarek L. Modulation of a calcium-sensitive nonspecific cation channel by closely associated protein kinase and phosphatase activities. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 10938-10943. PMID: 9724808, PMCID: PMC27999, DOI: 10.1073/pnas.95.18.10938.Peer-Reviewed Original ResearchConceptsProtein kinaseCation channelsProtein phosphatase 1Protein tyrosine phosphataseNonspecific cation channelProtein kinase C inhibitorPresence of H7Nonhydrolyzable ATP analogKinase C inhibitorRegulatory complexPhosphatase 1Bag cell neuronsTyrosine phosphataseExcised patchesOpen probabilityCytoplasmic sideMolecular switchATP analogC inhibitorPhosphatase activityKinaseChannel closureSpontaneous action potentialsPatch-clamp studiesATPThe Expression of Two Splice Variants of the Kv3.1 Potassium Channel Gene Is Regulated by Different Signaling Pathways
Liu S, Kaczmarek L. The Expression of Two Splice Variants of the Kv3.1 Potassium Channel Gene Is Regulated by Different Signaling Pathways. Journal Of Neuroscience 1998, 18: 2881-2890. PMID: 9526005, PMCID: PMC6792597, DOI: 10.1523/jneurosci.18-08-02881.1998.Peer-Reviewed Original ResearchMeSH KeywordsAlternative SplicingAnimalsCerebellumFibroblast Growth FactorsGene Expression Regulation, DevelopmentalMembrane PotentialsNerve Growth FactorsNeuropeptidesPotassium ChannelsPotassium Channels, Voltage-GatedProtein Kinase CRatsRats, Sprague-DawleyRNA, MessengerSecond Messenger SystemsShaw Potassium ChannelsSignal TransductionTranscription, GeneticConceptsDifferent signaling pathwaysKv3.1 potassium channel genePotassium channel genesBasic fibroblast growth factorChannel genesSignaling pathwaysNuclear protein kinase C activityMRNA levelsDifferent channel proteinsProtein kinase C inhibitorProtein kinase C activityKinase C inhibitorKinase C activityAlternative splicingNuclear RNAChannel proteinsMolecular mechanismsFibroblast growth factorDifferential regulationDevelopmental stagesSplice variantsC inhibitorPKC activityC activityGenes
1993
Studies on regulation of the ascorbic acid transporter in a cell line derived from rabbit non-pigmented ciliary epithelium
Delamere N, Coca-Prados M, Aggarwal S. Studies on regulation of the ascorbic acid transporter in a cell line derived from rabbit non-pigmented ciliary epithelium. Biochimica Et Biophysica Acta 1993, 1149: 102-108. PMID: 8391316, DOI: 10.1016/0005-2736(93)90030-4.Peer-Reviewed Original ResearchConceptsProtein kinase CKinase CAscorbate uptakeCell linesProtein kinase C inhibitorProtein kinase C activatorCultured cell linesPresence of staurosporineKinase C inhibitorAscorbic acid transporterNon-pigmented ciliary epitheliumAscorbate transporterUptake rateAcid transportersC activatorCiliary epitheliumC inhibitorNon-pigmented epithelial cellsPDBu treatmentUptake mechanismEpithelial cellsPDBu effectSodium gradientTransportersCells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply